Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.
Saved in:
| Title: | Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial. |
|---|---|
| Authors: | Naicker V; South African Medical Research Council, Durban, South Africa., Laher F; Faculty of Health Sciences, Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Bekker LG; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa., Seaton KE; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Allen M; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., De Rosa S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Yates NL; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Mkhize NN; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Saunders K; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Heptinstall J; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Malahleha M; Synergy Biomed Research Institute, East London, South Africa., Mngadi K; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa., Daniels B; South African Medical Research Council, Durban, South Africa., Innes C; Aurum Institute, Klerksdorp Research Centre, Klerksdorp, South Africa., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Modise T; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Bekker V; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Furch B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Miner MD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Phogat S; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.; GSK, Wavre, Belgium., Diazgranados CA; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America., Gurunathan S; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America., Koutsoukos M; GSK, Wavre, Belgium., Van Der Meeren O; Previously GSK, Rixensart, Belgium., Roxby AC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.; University of Washington Departments of Medicine and Global Health, Seattle, Washington, United States of America., Ferrari G; Department of Surgery, Center for Human System Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America., Morris L; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa., Montefiori D; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Tomaras GD; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. |
| Source: | PLOS global public health [PLOS Glob Public Health] 2024 Sep 20; Vol. 4 (9), pp. e0003319. Date of Electronic Publication: 2024 Sep 20 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 9918283779606676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-3375 (Electronic) Linking ISSN: 27673375 NLM ISO Abbreviation: PLOS Glob Public Health Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
